As Seen In
BioWatch News – RepliCel as a Featured Company in June’s Issue Exploring Alopecia and its Industry
Cell therapies for curing alopecia are early in their clinical development. These must still show evidence of durable and robust efficacy. Nevertheless, it bears watching. Regenerative cell therapies are making swift, genuine strides in treating specific human organs such as the hart. We expect these gains to extend towards rejuvenating hair follicles.
Among cell therapy companies in the alopecia space, tiny RepliCel Life Sciences in Vancouver, BC, is furthest into human testing. RepliCel originally started trading on the OTC bulletin board (OTCQB: REPCF) and was recently added to the Toronto Stock Exchange (TSXV: RP)
Replicel Life Sciences is developing its proprietary cell therapy approach designed RCH-01. It aims to rejuvenate damaged, miniaturized hair follicles in balding scalp skin. It focuses on correcting a deficit of healthy dermal sheath cup cells (DSCs) in the follicle.
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.
THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.